Lophius raises €4.25m from Bayern Kapital et al.

Lophius will use the proceeds to continue development of its T cell-based research tools and expand the company's in-vitro diagnostic programs to tuberculosis. The business stated there are 9.5 million new tuberculosis cases per year worldwide and 450,000 cases reported for Europe.

Bayern Kapital manages 11 investment funds with a total volume of €340m. So far, it has invested €227m in 245 technology companies in sectors including life sciences, software and IT, medical technology, nanotechnology and environmental technology.

Company
Founded in 2002 and based in Regensburg, Lophius Biosciences is a biotech company developing T cell-based research tools, doing contract research and diagnostics for functional assessment of pathogen/disease-reactive T cells.

The company aims to improve therapy control and personalised treatment of patients in the areas of transplantation medicine, infectious and autoimmune diseases.

People
Bayern Kapital – Roman Huber (managing director).
Lophius – Robert Phelps, Bernd Merkl (co-CEOs, managing directors).
VRD – Thomas Hartwig (managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Venture